Khuanekkaphan Monsicha, Netsomboon Kesinee, Fristiohady Adryan, Asasutjarit Rathapon
Thammasat University Research Unit in Drug, Health Product Development and Application (DHP-DA), Department of Pharmaceutical Sciences, Faculty of Pharmacy, Thammasat University, Pathum Thani 12120, Thailand.
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Thammasat University, Pathum Thani 12120, Thailand.
Pharmaceutics. 2024 Sep 30;16(10):1276. doi: 10.3390/pharmaceutics16101276.
Melanoma is a skin cancer that requires early treatment to prevent metastasis. In particular, the superficial spreading melanoma, excisional surgery with local administration of anti-cancer drugs via microneedles is currently considered a potential combination therapy. Quercetin is a natural flavonoid having activities against melanoma cells. Unfortunately, the therapeutic effect is limited by its poor water solubility. This study aimed to develop formulations of solid dispersion-loaded dissolving microneedles (SD-DMNs) of quercetin and to investigate their in vitro activities against melanoma cells. : Quercetin solid dispersions (Q-SDs) were prepared using polyvinylpyrrolidone K30 (PVP) via a solvent technique. The optimized Q-SD was selected for preparing Q-SD-loaded dissolving microneedles (Q-SD-DMNs) using a mold casting method. : Q-SDs had higher water solubility than that of quercetin by 5-10 times depending on the ratio of quercetin-to-PVP. The presence of quercetin in the Q-SD and Q-SD-DMN were in an amorphous form. The obtained Q-SD-DMNs had pyramid-shaped microneedles. Their strength depended on the compositions, i.e., ratios of hyaluronic acid-to-sodium carboxymethylcellulose and the content of Q-SD. An optimized Q-SD-DMN increased the in vitro skin permeation of quercetin compared to that of microneedles containing quercetin (without being processed). From the molecular investigations, the optimized Q-SD-DMN reduced the viability of the A375 cells (melanoma cells) through the induction of cell apoptosis. It suppressed Bcl-2 gene expression and led to a lower content of Bcl-2 in the cells. The optimized Q-SD-DMN has a potential for use in further in vivo studies as a synergistic method of melanoma treatment.
黑色素瘤是一种需要早期治疗以防止转移的皮肤癌。特别是浅表扩散性黑色素瘤,通过微针局部给药进行切除手术目前被认为是一种潜在的联合治疗方法。槲皮素是一种对黑色素瘤细胞具有活性的天然黄酮类化合物。不幸的是,其治疗效果受到水溶性差的限制。本研究旨在开发槲皮素的固体分散体负载溶解微针(SD - DMN)制剂,并研究其对黑色素瘤细胞的体外活性。:采用溶剂法使用聚乙烯吡咯烷酮K30(PVP)制备槲皮素固体分散体(Q - SD)。选择优化后的Q - SD,采用铸模法制备负载Q - SD的溶解微针(Q - SD - DMN)。:根据槲皮素与PVP的比例,Q - SD的水溶性比槲皮素高5 - 10倍。Q - SD和Q - SD - DMN中槲皮素以无定形形式存在。所制备的Q - SD - DMN具有金字塔形微针。其强度取决于组成,即透明质酸与羧甲基纤维素钠的比例以及Q - SD的含量。与含槲皮素(未处理)的微针相比,优化后的Q - SD - DMN增加了槲皮素的体外皮肤渗透。从分子研究来看,优化后的Q - SD - DMN通过诱导细胞凋亡降低了A375细胞(黑色素瘤细胞)的活力。它抑制了Bcl - 2基因表达,并导致细胞中Bcl - 2含量降低。优化后的Q - SD - DMN有潜力作为黑色素瘤治疗的协同方法用于进一步的体内研究。